Surgically Metabolic Resection of Pericardial Fat to Ameliorate Myocardial Mitochondrial Dysfunction in Acute Myocardial Infarction Obese Rats.

OBJECTIVE

Recognition of homologous recombination deficiency (HRD) has revolutionized ovarian cancer (OC) treatment paradigm. Our study aimed to determine the prevalence of HRD in Taiwanese patients with high-grade serous ovarian cancer (HGSOC), high-grade endometrioid ovarian cancer (HGEOC), primary peritoneal cancer (PPC), and/or fallopian tube cancer (FTC).

METHODS

The HALO-Taiwan, a cross-sectional, noninterventional study (NCT04991051) enrolled patients with stage III/IV HGSOC, HGEOC, PPC, or FTC having formalin-fixed paraffin-embedded tumor tissue blocks collected within the past 120 days of enrollment. The primary outcome was the prevalence of HRD. The secondary outcomes included prevalence of BRCA wild-type and loss of heterozygosity (LOH) positive status, tumor BRCA1/2 mutations, and other pathogenic mutations. The association of LOH status with demographic factors and pathogenic mutations was assessed using Cramer's V.

RESULTS

Of 68 patients (median age [range]: 60.0 [39.0-81.0] years) enrolled, the majority (92.6%) had primary OC followed by PPC (2.9%) and FTC (4.4%). The overall prevalence of HRD was 52.9%; 14.7% had tumor BRCA mutations, and 38.2% had BRCA wild-type LOH-positive status. LOH status showed a strong, significant positive correlation with age and ECOG status (V=0.50, p=0.027, for both).

CONCLUSION

The HALO-Taiwan was the first observational study reporting HRD prevalence of 52.9% among patients with advanced OC in Taiwan. Our findings underscore the need to implement guideline-recommended testing for HRD as a part of the initial diagnostic work-up for all newly-diagnosed advanced high-grade OC patients to optimize treatment strategies.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04991051.